Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 6/20 | 0.64 |
| ▸ | IGF1R | P08069 | 12/20 | 0.46 |
| ▸ | INSR | P06213 | 5/20 | 0.43 |
| ▸ | LYN | P07948 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | FLT4 | P35916 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
| ▸ | MARK3 | P27448 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | BLK | P51451 | 2/20 | 0.43 |
| ▸ | NEK2 | P51955 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076645 | 0.97 | ACVRL1 (0.63) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14531310 | 0.91 | ACVRL1 (0.51) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL5076796 | 0.91 | ACVRL1 (0.51) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL5080301 | 0.90 | ACVRL1 (0.50) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL5076699 | 0.89 | ACVRL1 (0.51) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14313452 | 0.89 | ACVRL1 (0.49) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14312895 | 0.87 | IGF1R (0.49) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14313201 | 0.87 | IGF1R (0.49) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14313448 | 0.87 | ACVRL1 (0.47) | ACVRL1IGF1RINSRLYNROCK2 | |
| SCHEMBL14312887 | 0.86 | IGF1R (0.49) | ACVRL1IGF1RINSRLYNROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | ACVRL1 336/4885IGF1R 1/4885INSR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.